Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

NNuvation Bio Inc.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
N

Nuvation Bio Inc.

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • News
  • Insider Transactions

News

News

  • Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer
    Sep 17, 2026Nuvation Bio Inc. Press Releases
  • Taletrectinib Across Key Subgroups in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From TRUST-I and TRUST-II
    Sep 15, 2026NUVATION BIO, INC.

    The post Taletrectinib Across Key Subgroups in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From TRUST-I and TRUST-II appeared first on NUVATION BIO, INC..

  • Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer
    Sep 15, 2026Nuvation Bio Inc. Press Releases
  • Nuvation Bio to Participate in Upcoming Investor Conferences
    Sep 2, 2026Nuvation Bio Inc. Press Releases
  • Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma
    Aug 20, 2026Nuvation Bio Inc. Press Releases
  • Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
    Aug 6, 2026Nuvation Bio Inc. Press Releases
  • Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
    Aug 4, 2026Nuvation Bio Inc. Press Releases
  • Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
    Jul 22, 2026Nuvation Bio Inc. Press Releases
  • Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma
    Jul 20, 2026Nuvation Bio Inc. Press Releases
  • Comparative Efficacy of Taletrectinib Versus First-Generation TKIs in TKI-Naïve ROS1+ Non-Small Cell Lung Cancer: A Matching-Adjusted Indirect Comparison
    Jul 20, 2026NUVATION BIO, INC.

    The post Comparative Efficacy of Taletrectinib Versus First-Generation TKIs in TKI-Naïve ROS1+ Non-Small Cell Lung Cancer: A Matching-Adjusted Indirect Comparison appeared first on NUVATION BIO, INC..

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • News
  • Insider Transactions